Azar Fadi M, Birs Antoinette S, Bui Quan M, Wettersten Nicholas, Tran Hao A, Kearns Mark J, Pretorius Victor, Urey Marcus A
Department of Medicine, University of California San Diego, San Diego, CA.
Division of Cardiovascular Medicine, Department of Medicine, University of California San Diego, San Diego, CA.
JHLT Open. 2025 Jun 26;9:100330. doi: 10.1016/j.jhlto.2025.100330. eCollection 2025 Aug.
Heart transplantation (HTx) remains the definitive therapy for select patients with Stage D heart failure. Donation after circulatory death (DCD) has emerged as a promising strategy to expand the donor pool, with studies showing comparable survival to donation after brain death (DBD). However, little is known about how DCD impacts post-transplant quality of life. Days alive and out of the hospital (DAOH) at 1 year is a validated, patient-centered metric reflecting both post-transplant morbidity and survival.
We conducted a single-center, retrospective cohort study of 226 adult patients who underwent HTx between January 2021 and June 2023 (117 DBD and 109 DCD recipients). The primary outcome was DAOH at 1 year. Secondary outcomes included post-transplant graft function, inotrope and intensive care unit (ICU) duration, readmissions, and mortality. Baseline characteristics and outcomes were compared using appropriate statistical methods, and quantile regression was used to adjust for clinical confounders.
Baseline characteristics were largely similar, although DBD recipients had higher pre-operative acuity. Median DAOH at 1 year did not differ significantly between DBD and DCD recipients (344 vs 343 days; = 0.896). Adjusted analyses confirmed no clinically meaningful difference. Secondary outcomes, including 1-year mortality, ICU stay, and readmission rates, were also comparable.
In this cohort, DCD recipients achieved similar DAOH at 1 year compared to DBD recipients, supporting the use of DCD as a viable strategy in HTx. This is one of the first studies to compare post-transplant quality of life in DBD and DCD HTx recipients.
心脏移植(HTx)仍然是特定D期心力衰竭患者的确定性治疗方法。循环死亡后器官捐献(DCD)已成为扩大供体库的一种有前景的策略,研究表明其生存率与脑死亡后器官捐献(DBD)相当。然而,关于DCD如何影响移植后生活质量知之甚少。1年时的存活出院天数(DAOH)是一个经过验证的、以患者为中心的指标,反映了移植后的发病率和生存率。
我们对2021年1月至2023年6月期间接受HTx的226例成年患者进行了一项单中心回顾性队列研究(117例DBD受者和109例DCD受者)。主要结局是1年时的DAOH。次要结局包括移植后移植物功能、血管活性药物使用情况和重症监护病房(ICU)住院时间、再入院情况和死亡率。使用适当的统计方法比较基线特征和结局,并使用分位数回归来调整临床混杂因素。
尽管DBD受者术前病情较重,但基线特征在很大程度上相似。DBD和DCD受者1年时的DAOH中位数无显著差异(344天对343天;P = 0.896)。校正分析证实无临床意义上的差异。包括1年死亡率、ICU住院时间和再入院率在内的次要结局也相当。
在该队列中,DCD受者1年时的DAOH与DBD受者相似,支持将DCD作为HTx的一种可行策略。这是首批比较DBD和DCD心脏移植受者移植后生活质量的研究之一。